News stories about Nektar Therapeutics (NASDAQ:NKTR) have been trending somewhat positive on Saturday, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nektar Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.6475510197657 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Nektar Therapeutics (NKTR) CEO Sells $4,640,814.77 in Stock (americanbankingnews.com)
- BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Bayer Of Co-Development, License, Co-Promotion Agreement (NKTR) (markets.businessinsider.com)
- Nektar Therapeutics down 1% premarket after Bayer bails on agreement to develop inhaled amikacin (seekingalpha.com)
- ‘Notable Upside Options Positioning’ in Nektar Therapeutics (NKTR) Highlights ‘Speculative Bullish Bias’ Over the Next Month -Susquehanna (streetinsider.com)
- Investor’s Roundup (Risk Factors in Focus) – Nektar Therapeutics, (NASDAQ: NKTR) – Stock Watch (stocksnewstimes.com)
A number of analysts have issued reports on NKTR shares. Mizuho lifted their price objective on Nektar Therapeutics from $30.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, November 14th. Jefferies Group reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Nektar Therapeutics in a research note on Wednesday, November 8th. Canaccord Genuity lifted their price objective on Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, November 13th. ValuEngine raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, J P Morgan Chase & Co reaffirmed a “buy” rating and issued a $44.00 price objective on shares of Nektar Therapeutics in a research note on Monday, November 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the stock. Nektar Therapeutics has a consensus rating of “Buy” and an average price target of $35.58.
Nektar Therapeutics (NASDAQ:NKTR) traded up $1.85 on Friday, reaching $56.90. The company had a trading volume of 3,711,607 shares, compared to its average volume of 2,428,364. Nektar Therapeutics has a one year low of $11.41 and a one year high of $57.83. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99.
Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.16. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The company had revenue of $152.90 million during the quarter, compared to analysts’ expectations of $126.50 million. During the same quarter in the previous year, the business earned ($0.32) EPS. Nektar Therapeutics’s revenue was up 321.2% compared to the same quarter last year. research analysts forecast that Nektar Therapeutics will post -0.75 earnings per share for the current fiscal year.
In related news, SVP Ivan P. Gergel sold 100,000 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $24.14, for a total transaction of $2,414,000.00. Following the completion of the transaction, the senior vice president now owns 84,871 shares in the company, valued at approximately $2,048,785.94. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Howard W. Robin sold 83,333 shares of the business’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $55.69, for a total value of $4,640,814.77. Following the transaction, the chief executive officer now owns 272,768 shares of the company’s stock, valued at approximately $15,190,449.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 941,427 shares of company stock valued at $27,509,448. 6.10% of the stock is owned by company insiders.
WARNING: “Nektar Therapeutics (NASDAQ:NKTR) Earning Somewhat Favorable Media Coverage, Study Shows” was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.truebluetribune.com/2017/12/17/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-nektar-therapeutics-nktr-stock-price.html.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.